Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Deep versus moderate neuromuscular blockade during total hip replacement
NL-OMON51748Phase 4Completed
- Sponsor
- Radboud University Medical Center
- Start
- Nov 2022
- Modality
- Small Molecules, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4, randomised trial of rocuronium and Sugammadex in osteoarthritis (OA) and hip osteoarthritis (2 arms), sponsored by Radboud University Medical Center. Primary endpoint: Quality of recovery at postoperative day 1. Started Nov 2022; status: completed.
02
Drugs
rocuroniumSugammadex
03
Conditions
osteoarthritis (OA)hip osteoarthritis
Beyond the preview
Go deeper on NL-OMON51748.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON51748.